Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
September 30 2019 - 7:30AM
Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA
(mRNA) therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced that Ronald Renaud, chief
executive officer, will participate in a fireside chat at the 3rd
Annual Chardan Genetic Medicines Conference in New Yok, NY, on
Monday, October 7, 2019, at 11:00 a.m. ET.
A live webcast of the session will be accessible through the
“Events and Presentations” page of the Company's website at
investors.translate.bio. A replay of the webcast will be archived
on the Translate Bio’s website for 30 days following the
presentation.
About Translate BioTranslate Bio is a
clinical-stage mRNA therapeutics company developing a new class of
potentially transformative medicines to treat diseases caused by
protein or gene dysfunction. The Company’s MRT platform is designed
to develop product candidates that deliver mRNA carrying
instructions to produce intracellular, transmembrane and secreted
proteins for therapeutic benefit. Translate Bio is
primarily focused on applying its MRT platform to pulmonary
diseases caused by insufficient protein production or where
production of proteins can modify disease. The Company also
believes its technology is applicable to a broad range of diseases,
including diseases that affect the liver, eye and central nervous
system. Additionally, the MRT platform may be applied to various
classes of treatments, such as therapeutic antibodies or vaccines
in areas such as infectious disease and oncology. Translate Bio’s
lead program is being developed as a treatment for cystic fibrosis
(CF) and is in an ongoing Phase 1/2 clinical trial. For more
information about the Company, please visit www.translate.bio or on
Twitter at @TranslateBio.
Contacts for Translate Bio
Investors
Teri Dahlman
tdahlman@translate.bio
857-242-7792
MediaMaura
Gavaghanmgavaghan@translate.bio857-242-7789
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024